Evidence map›Paper›PMID 41245886›Full record

ArticleMedComm2025

Applying Genetic Risk Score to Improve Risk Assessment of New-Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large-Scale Prospective Cohort Study.

Yufang Ding, Mucong Li, Wei Bai, Junyan Qian, Mengzhuo Cao, Jian Xu, Xinwang Duan, Hui Luo, Cheng Zhao, Feng Zhan and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Yufang DingDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Mucong LiDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Wei BaiDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Junyan QianDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Mengzhuo CaoDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Jian XuDepartment of Rheumatology and Immunology First Affiliated Hospital of Kunming Medical University Kunming China.
Xinwang DuanDepartment of Rheumatology The Second Affiliated Hospital of Nanchang University Nanchang China.
Hui LuoDepartment of Rheumatology and Immunology Second Xiangya Hospital of Central South University Changsha China.
Cheng ZhaoDepartment of Rheumatology and Immunology The People's Hospital of Guangxi Zhuang Autonomous Region Nanning China.
Feng ZhanDepartment of Rheumatology and Immunology Hainan General Hospital Haikou China.
Min YangDepartment of Rheumatic & TCM Medical Center Nanfang Hospital Southern Medical University Guangzhou China.
Rui WuDepartment of Rheumatology The First Affiliated Hospital of Nanchang University Nanchang China.
Lijun WuDepartment of Rheumatology and Immunology People's Hospital of Xinjiang Uygur Autonomous Region Urumqi China.
Zhen ChenDepartment of Rheumatology The Second Affiliated Hospital of Fujian Medical University Quanzhou China.
Wei WeiDepartment of Rheumatology and Immunology Tianjin Medical University General Hospital Tianjin China.
Yang XuPeking University Clinical Research Institute, Peking University First Hospital Beijing China.
Shangzhu ZhangDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Xiaomei LengDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Qian WangDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Xinping TianDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Pei GaoDepartment of Epidemiology and Biostatistics School of Public Health Peking University Beijing China.
Xiaofeng ZengDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Xinzhuang YangCenter For bioinformatics, National Infrastructures for Translational Medicine Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
Mengtao LiDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.
Jiuliang ZhaoDepartment of Rheumatology and Clinical Immunology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus nephritis (LN) is one of the most severe manifestation of systemic lupus erythematosus (SLE). However, reliable tools for predicting LN risk remain limited. In this multicenter prospective cohort study, we developed, validated, and refined a risk stratification model for new-onset LN. A total of 2441 SLE patients without baseline renal involvement were consecutively enrolled from the Chinese SLE Treatment and Research (CSTAR) registry, with 215 (8.8%) developed LN in a median follow-up time of 3.5 years. A combination of clinical predictors, age < 30 years, absence of arthritis, serositis, hypocomplementemia, and positive anti-double-stranded DNA antibodies identified a clinical high-risk group (

Indexed as

genetic risk scorelupus nephritisrisk factorssystemic lupus erythematosus

Identifiers

PMID41245886
PMCPMC12618856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.